Internet and tablet-based cognitive tests were trendy at CTAD. If they prove their worth, they may provide a quicker and cheaper way to screen large numbers of people for trials, and track cognitive decline more accurately.
Researchers at CTAD advanced tau research on several fronts, correlating tau PET with Braak stage and memory loss, and introducing a new tau model and therapeutic antibody.
Chemical mutagenesis yields an SOD1 variant found in people with the disease. Neurons degenerate without overexpression of the enzyme.
Using creative ways of mining genetic data, researchers are coming up with new risk variants for Alzheimer’s.
Researchers at CTAD announced the end for two active immunotherapies, along with the curious story of a placebo as a treatment and the start of a new antibody.
Researchers at CTAD reported seeing biomarkers budge in active and passive immunotherapy trials, but measurement techniques and screening protocols still need improvement for early stage trials to succeed.
A CAP symposium opened the CTAD conference, indicating that presymptomatic treatment and “federated” research have become mainstream thinking in Alzheimer’s therapy development. EPAD is pulling together European sites.
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
The amino terminus toggles between a neatly folded nucleic acid-binding domain and a disorganized configuration that forms inclusions.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
CTAD Shows Alzheimer’s Field Trying to Reinvent Itself Rusty Unleashed: Forget Disease Modification, Go For Big Effect From Shared CAP, Secondary Prevention Trials are Off and Running Immunotherapy I: Baby Steps, but No Breakthroughs Immunotherapy II: ...
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.